All News

hands pregnant

LLDAS: Predicting Pregnancy Outcomes

d Sheila Reyes, MD

Pregnancy in SLE is a high risk situation and active disease can lead to fetal loss, pre-term birth, IUGR and neonatal lupus syndromes. In a study by Dr. Michelle Petri and colleagues, they evaluated whether the LLDAS at the start of pregnancy was predictive of pregnancy outcome.

Read Article
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

Awesome succinct guidelines!#acrbest #acr20 @RheumNow https://t.co/lzLykOY8G0

Links:

alexa meara lexmeara ( View Tweet)

VEXAS! Hot topic of the year #ACR2020 ABS#1953 @RheumNow https://t.co/RIQKsoWbHe

Links:

Bella Mehta bella_mehta ( View Tweet)

Mavrilimumab (anti GM-CSF receptor α Mab) efficacious in maintaining disease remission in GCA pts. Phase 2 trial (n=70) 1⃣Disease flare 19% in tx vs. 46% in PBO at 26wk 2⃣Sustained remission 83% vs. 50% in PBO 3⃣Similar AE in both groups @RheumNow #ACR20 Abs#L06 https://t.co/LqiNKJffFo
Robert B Chao, MD doctorRBC ( View Tweet)
@RheumNow #ACR20 Abs L08 Prospective 4 year PROBE trial of Febuxostat vs allopurinol long term CV safety: febuxostat was not associated w/increased risk of death compared w/allopurinol. 222 (7·2%) pts died in the febuxostat group compared to 263 (8·6%) in the allopurinol group

Olga Petryna DrPetryna ( View Tweet)

#ACR20 @RheumNow https://t.co/ImXVcDIl4V

Links:

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Listen to part III of our #ACR20 Day 3 recap. Follow the link below or find us on Apple podcasts. https://t.co/sTxhkccumn https://t.co/OQFBE575P8

Links:

Dr. John Cush RheumNow ( View Tweet)
Abst#1717 confirms that early start of csDMARDs as 1st line tx & keeping ts/bDMARD as 2nd line tx (or more) is associated w/ a favorable outcome at 10 yrs in the ESPOIR cohort (a French multi-center cohort that followed patients w/ early RA). #ACR20 @RheumNow https://t.co/bzZiShCF97
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
This - very cool. Not as impressive as the implanted vagal stimulation pilot data, but once a day and well tolerated. Very early days but enticing, we will see! #ACR20 ABST1995 @RheumNow https://t.co/QZ8npob2H9 https://t.co/fRlFwIHqky

Links:

David Liew drdavidliew ( View Tweet)
Wonder if you can predict development of clinical RA in those at risk either w/ a - +RF or +CCP - Relevant sxs w/ or w/o abs - 1st deg relatives do RA pts? Abst#1722 shows patterns of pain or degree of jt swelling from SPARRA Qnairre can do so. #ACR20 @RheumNow https://t.co/bQ4ZmSYhBe
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr. Khanna NOVESA study #ACR20 Abst#L09. Autotaxin inhibitor ZIRI in early dcSSc. 21 pts ziri vs 12 PBO. mRSS at Wk24 mean difference -2.8. Ziri well-tolerated. Would be great for new drug for early SSc skin. @RheumNow. https://t.co/qpvLFsAe0x
Eric Dein ejdein1 ( View Tweet)
FAST trial: allopurinol vs febuxostat on safety (for gout pts on allopurinol, with ≥1 CV RF, TTT dosing) febuxostat non-inferior for CV events Well, that's a relief. gout flare similar, good follow-up, colchicine did not influence out in Lancet today? #ACR20 ABSTL08 @RheumNow https://t.co/5LeXV5mgu9
David Liew drdavidliew ( View Tweet)
RITAZAREM trial long-term follow-up -RTX vs AZA after RTX-induced remission in ANCA #vasculitis -RTX superior to AZA to prevent relapse -Relapse common regardless of therapy; high-dose RTX not effective beyond treatment period Abs#2052 #ACR20 @RheumNow https://t.co/bW7IaMnVCG

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

Physicians must perceive the patient as a person rather than a carrier of a disease disease - Eric Cassell. Check out this book, and other insights from @LCalabreseDO on patient/provider discordance #empathy #cleclinicrheum @HealioRheum @RheumNow https://t.co/f5jnUS701X
Cassandra Calabrese CCalabreseDO ( View Tweet)
#ACR20 @RheumNow https://t.co/0Kfe3Zforl

Links:

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

@SSNaushon MTX remains backbone of therapy given low cost, safety profile, and long experience with it. Majority of pts do well on MTX and do not require TNFi @Rheumnow.

Eric Dein ejdein1 ( View Tweet)

Interesting Swedish abstract 1997 at #ACR20. Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?

Jeffrey Curtis RADoctor ( View Tweet)

L06: Mavrilimumab in #GCA ⭐️Efficacy and safety of MAV maintaining sustained remission 26w new and relapsing/ref #GCA Flare risk ➡️ 62% risk ⬇️ of flare w/ MAV Sustained remission➡️ 33% ⬆️ in MAV No diff in new or relapsing/ref pts, No diff in AE #ACR20 #ACRambassador

Sebastian E. Sattui MD, MS SattuiSEMD ( View Tweet)

Fantastic session about the 2020 guidelines for management of RA! Soon to be published. One major difference from 2015 guidelines ➡️ Conditional recommendation to choose a Biologic over Triple Therapy in MTX-inadequate responders (Discussion about patient preference is key!) https://t.co/s016piIN7Q

Links:

Dr. Tina Mahajan drtinamahajan ( View Tweet)

×